Yükleniyor... / Loading...
This study evaluates low-frequency electromagnetic resonance therapy (LF-EMR), compared with an inactive (sham) device and low-dose Naltrexone (LDN), in people with a systemic autoimmune disorder. People aged 18 to 70 with a confirmed diagnosis for at least 12 months of an autoimmune disease such as systemic lupus erythematosus, rheumatoid arthritis or multiple sclerosis may take part. The study is in Phase 1/Phase 2 and is enrolling participants by invitation.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: 1. Male or female participants aged 18-70 years. 2. Clinical diagnosis of a systemic autoimmune disorder (e.g., systemic lupus erythematosus, rheumatoid arthritis, or multiple sclerosis) confirmed for at least 12 months. 3. Stable disease-modifying therapy or corticosteroid regimen for at least 8 weeks prior to enrollment. 4. Willingness to maintain current medication schedule for the duration of the study. 5. Ability to provide written informed consent and comply with study procedures. 6. Access to stable internet or smartphone connection for digital consent verification and symptom tracking. Exclusion Criteria: 1. Presence of an implanted medical or electronic device (e.g., pacemaker, defibrillator, deep brain stimulator). 2. Pregnancy or lactation. 3. Active infection, malignancy, or significant hepatic, renal, or cardiovascular disease. 4. Known photosensitivity, seizure disorder, or history of uncontrolled epilepsy. 5. Prior participation in any electromagnetic or quantum resonance study within the past 6 months. 6. Use of biologic or investigational therapy initiated within the previous 3 months. 7. Inability to attend at least 80% of treatment sessions or follow-up visits.